Adult Liver Disease Prognostic Modelling for Long-term Outcomes in Biliary Atresia: An Observational Cohort Study.
Journal
Journal of pediatric gastroenterology and nutrition
ISSN: 1536-4801
Titre abrégé: J Pediatr Gastroenterol Nutr
Pays: United States
ID NLM: 8211545
Informations de publication
Date de publication:
01 07 2021
01 07 2021
Historique:
pubmed:
16
3
2021
medline:
13
7
2021
entrez:
15
3
2021
Statut:
ppublish
Résumé
To assess the utility of prognostic scoring systems for adolescents with biliary atresia (BA) surviving with native liver, for predicting the subsequent requirement for liver transplantation (LT). Single-centre retrospective analysis of 397 BA patients who received Kasai Portoenterostomy (KP) 1980-1996 and survived with the native liver at 16 years. Laboratory and clinical variables at 16 years (timepoint 16 years) were used to calculate (i) LT allocation scores; Model for End-Stage Liver Disease [MELD/MELD-sodium (Na)], and UK End-Stage Liver Disease (UKELD); (ii) Mayo Primary Sclerosing Cholangitis risk score (MayoPSC) and (iii) a modified Paediatric End-Stage Liver Disease (PELD) score. Scores were compared between patients requiring LT after 16 years of age (LT > 16 years), and those who survived with native liver, at the latest follow-up. Additional subgroup analysis for patients with data available at 12 years (timepoint 12 years). MELD (area under the receiver operating characteristic [AUROC] 0.847) and UKELD (AUROC: 0.815) at 16 years of age predict the need for LT > 16 years. No advantage for MELD-Na over MELD was demonstrated. MELD >8.5 and UKELD >47 predicted LT > 16 years with 84% and 79% sensitivity and 73% and 73% specificity. PELD had a similar performance to MELD, but superiority to UKELD. MayoPSC revealed predictive accuracy for LT >16 years (AUROC 0.859), with a score of >0.87 predicting LT > 16 years with 85% sensitivity and 82% specificity. At timepoint 12 years, MELD and MayoPSC predicted LT >16 years. Change in MELD, PELD and MayoPSC between 12 and 16 years of age, was associated with LT >16 years. Adult LT allocation scores may help monitor progress in adolescent BA, but the omission of relevant risk factors limits their utility for listing in this cohort. A BA-specific prognostic score would improve the management of adolescent BA.
Identifiants
pubmed: 33720092
doi: 10.1097/MPG.0000000000003116
pii: 00005176-202107000-00018
doi:
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
93-98Informations de copyright
Copyright © 2021 by European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Bijl EJ, Bharwani KD, Houwen RHJ, et al. The long-term outcome of the Kasai operation in patients with biliary atresia: a systematic review. Neth J Med 2013; 71:170–173.
Jain V, Burford C, Alexander EC, et al. Prognostic markers at adolescence in patients requiring liver transplantation for biliary atresia in adulthood. J Hepatol 2019; 71:71–77.
Lykavieris P, Chardot C, Sokhn M, et al. Outcome in adulthood of biliary atresia: a study of 63 patients who survived for over 20 years with their native liver. Hepatology 2005; 41:366–371.
Schilsky ML, Moini M. Advances in liver transplantation allocation systems. World J Gastroenterol 2016; 22:2922–2930.
Cholongitas E, Burroughs AK. The evolution in the prioritization for liver transplantation. Ann Gastroenterol 2012; 25:6–13.
Malinchoc M, Kamath PS, Gordon FD, et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000; 31:864–871.
Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33:464–470.
Biggins SW, Kim WR, Terrault NA, et al. Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology 2006; 130:1652–1660.
Neuberger J, Gimson A, Davies M, et al. Selection of patients for liver transplantation and allocation of donated livers in the UK. Gut 2008; 57:252–257.
Chang CH, Bryce CL, Shneider BL, et al. Accuracy of the Pediatric End-stage Liver Disease score in estimating pretransplant mortality among pediatric liver transplant candidates. JAMA Pediatr 2018; 172:1070–1077.
Leung DH, Narang A, Minard CG, et al. A 10-Year united network for organ sharing review of mortality and risk factors in young children awaiting liver transplantation. Liver Transpl 2016; 22:1584–1592.
Shneider BL, Suchy FJ, Emre S. National and regional analysis of exceptions to the pediatric end-stage liver disease scoring system (2003–2004). Liver Transplant 2006; 12:40–45.
Hsu EK, Mazariegos GV. Global lessons in graft type and pediatric liver allocation: a path toward improving outcomes and eliminating wait-list mortality. Liver Transpl 2017; 23:86–95.
Samyn M, Davenport M, Jain V, et al. Young people with biliary atresia requiring liver transplantation: a distinct population requiring specialist care. Transplantation 2019; 103:e99–e107.
Herden U, Grabhorn E, Briem-Richter A, et al. Developments in pediatric liver transplantation since implementation of the new allocation rules in Eurotransplant. Clin Transplant 2014; 28:1061–1068.
Neto JS, Carone E, Pugliese RPS, et al. Modified pediatric end-stage liver disease scoring system and pediatric liver transplantation in Brazil. Liver Transplant 2010; 16:426–430.
Braun HJ, Perito ER, Dodge JL, et al. Nonstandard exception requests impact outcomes for pediatric liver transplant candidates. Am J Transplant 2016; 16:3181–3191.
Liver Advisory Group. Liver Transplantation: Selection Criteria and Recipient Registration . 2019. Available at: https://nhsbtdbe.blob.core.windows.net/umbraco-assets-corp/17399/pol195.pdf . [Accessed 1 February]
Maggs JRL, Chapmane RW. An update on primary sclerosing cholangiti. Curr Opin Gastroenterol 2008; 24:377–383.
Wiesner RH, Grambsch PM, Dickson ER, et al. Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis. Hepatology 1989; 10:430–436.
Kim WR, Therneau TM, Wiesner RH, et al. A revised natural history model for primary sclerosing cholangitis. Mayo Clin Proc 2000; 75:688–694.
Dyson JK, Beuers U, Jones DEJ, et al. Primary sclerosing cholangitis. Lancet 2018; 391:2547–2559.
McDiarmid SV, Anand R, Lindblad AS. Development of a pediatric end-stage liver disease score to predict poor outcome in children awaiting liver transplantation. Transplantation 2002; 74:173–181.
Dhawan A, Samyn M, Joshi D. Young adults with paediatric liver disease: future challenges. Arch Dis Child 2017; 102:8–9.
Joshi D, Gupta N, Samyn M, et al. The management of childhood liver diseases in adulthood. J Hepatol 2017; 66:631–644.
Ebel NH, Hsu EK, Berry K, et al. Disparities in waitlist and posttransplantation outcomes in liver transplant registrants and recipients aged 18 to 24 years: analysis of the UNOS database. Transplantation 2017; 101:1616–1627.
Goldberg DS, Makar G, Bittermann T, et al. Center variation in the use of nonstandardized model for end-stage liver disease exception points. Liver Transplant 2013; 19:1330–1342.
Hsu EK, Shaffer M, Bradford M, et al. Heterogeneity and disparities in the use of exception scores in pediatric liver allocation. Am J Transplant 2015; 15:436–444.
Angeli P, Wong F, Watson H, et al. Hyponatremia in cirrhosis: results of a patient population survey. Hepatology 2006; 44:1535–1542.
Wai-Sun Wong V, Mei-Ling Chim A, Lai-Hung Wong G, et al. Performance of the new MELD-Na score in predicting 3-month and 1-year mortality in chinese patients with chronic hepatitis B. Liver Transplant 2007; 13:1228–1235.
Biggins SW, Rodriguez HJ, Bacchetti P, et al. Serum sodium predicts mortality in patients listed for liver transplantation. Hepatology 2005; 41:32–39.
Ruf AE, Kremers WK, Chavez LL, et al. Addition of serum sodium into the MELD score predicts waiting list mortality better than MELD alone. Liver Transplant 2005; 11:336–343.
Chapman R, Fevery J, Kalloo A, et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010; 51:660–678.